SEP 09, 2016
Treat-and-Extend Aflibercept for CRVO
ASRS 2016
03:51
Retina/Vitreous
In this interview from ASRS 2016, Dr. Rahul N. Khurana discusses results from the phase 4 NEWTON trial, which switched patients with central retinal vein occlusions CRVO) and recurrent macular edema from fixed interval bevacizumab or ranibizumab injections to treat-and-extend aflibercept. After intervention, 19/20 patients were able to increase their treatment interval by an average of 26 days, corresponding to approximately 4 fewer injections a year. Dr. Khurana states that aflibercept may be a more durable anti-VEGF agent for eyes with CRVO or those requiring chronic therapy.